← All trials
NCT06701721
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 25, 2024
- Primary completion
- Oct 31, 2025
- Completion date
- Feb 28, 2026
- First posted
- Nov 22, 2024
- Last posted
- Nov 22, 2024
- Enrollment
- 21
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Therini Bio Pty LtdLead sponsor
- Therini Bio Pty LtdOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.